Most Read Articles
23 Nov 2017
In patients with rheumatoid arthritis (RA) who are also positive for anticitrullinated protein antibodies (ACPA), tocilizumab (TCZ) treatment for 2 years increases femoral neck bone mineral density (BMD) and decreases concentrations of bone resorption markers, a recent study has found.
12 Nov 2017
Tocilizumab may improve skin score and forced vital capacity stabilization in patients with systemic sclerosis, while potentially increasing the risk of serious infections, according to the open-label data of the faSScinate* trial.
Audrey Abella, 21 Nov 2017
The infliximab (IFX) biosimilar SB2, whether administered long-term or switched from IFX, had comparable efficacy and safety as IFX for rheumatoid arthritis (RA), a study has found.
30 Nov 2017
There are significant associations between comorbidities and hand osteoarthritis (OA) disease burden, a recent study has found.

Thrombotic recurrence, organ damage likely in patients with primary antiphospholipid syndrome

17 Aug 2017

A large number of patients face new thrombotic events and organ damage in spite of therapy, while evolution toward connective tissue disease (CTD) is infrequent, according to a recent study.

Researchers retrospectively reviewed medical records of patients with primary antiphospholipid syndrome (PAPS) followed in six centres for ≥15 years to assess the long-term frequency of thrombotic recurrences, obstetrical complications, organ damage, severe comorbidities and evolution toward CTD in PAPS.

A total of 115 patients were analysed (mean age at diagnosis 33 years; 88 percent women) and followed between 1983 and 2014.

There were 50 patients (44 percent) who had at least a thrombotic event for a total of 75 events and an annual incidence of 3.5 percent during a median follow-up of 18 years (range, 15 to 30 years). Those with previous thrombotic history experienced more frequent thromboses (p=0.002).

Six patients (5 percent) had a catastrophic antiphospholipid syndrome. Oral anticoagulation did not appear to protect patients with thrombotic onset against recurrences (p=0.26).

Of the 87 pregnancies in 52 women, 78 percent were successful. Functional damage occurred in 29 percent of patients. Patients with a thrombotic history (p=0.004) were likely to accrue damage, which was also significantly associated with arterial events (p<0.001), especially stroke, but not with demographics, serology or treatment.

A total of 14 major bleeding episodes were recorded in 18 patients who received anticoagulants. Severe infections affected six patients (5 percent), with one fatality. Eight patients (7 percent) had a diagnosis of a solid cancer.

In total, 16 patients (14 percent) developed an autoimmune disease and 13 (11 percent) a full-blown picture of CTD, according to researchers.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Rheumatology digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
23 Nov 2017
In patients with rheumatoid arthritis (RA) who are also positive for anticitrullinated protein antibodies (ACPA), tocilizumab (TCZ) treatment for 2 years increases femoral neck bone mineral density (BMD) and decreases concentrations of bone resorption markers, a recent study has found.
12 Nov 2017
Tocilizumab may improve skin score and forced vital capacity stabilization in patients with systemic sclerosis, while potentially increasing the risk of serious infections, according to the open-label data of the faSScinate* trial.
Audrey Abella, 21 Nov 2017
The infliximab (IFX) biosimilar SB2, whether administered long-term or switched from IFX, had comparable efficacy and safety as IFX for rheumatoid arthritis (RA), a study has found.
30 Nov 2017
There are significant associations between comorbidities and hand osteoarthritis (OA) disease burden, a recent study has found.